Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol

• Fei Chen,
• Jinghe Lang,
• Peter Hillemanns,
• Youzhong Zhang,
• Zoltán Novák,
• Long Sui,
• Ling Han,
• Christian Dannecker,
• Ctirad Mokráš,
• Zhixue You

Affiliations

Fei Chen

Harbour Biomed, Shanghai, China

Jinghe Lang

Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China

Peter Hillemanns

10 Department of Gynecology and Obstetrics, Medizinische Hochschule, Hannover, Germany

Youzhong Zhang

Departments of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.

Zoltán Novák

Department of Obstetrics and Gynecology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary; and

Long Sui

Obstetrics & Gynecology Hospital of Fudan University, Shanghai, PR China.

Ling Han

Department of Oncology, Tianjin Beichen Hospital, Tianjin, China

Christian Dannecker

Department of Obstetrics and Gynaecology, University Hospital Augsburg, Augsburg, Germany

Ctirad Mokráš

MCM GYNPED, s.r.o, Dubnica nad Vahom, Slovakia

Zhixue You

Department of Obstetrics and Gynecology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China